Correlations in Palmitoylation and Multiple Phosphorylation of Rat Bradykinin B2 Receptor in Chinese Hamster Ovary Cells*

Vukic SoskicDagger , Elke NyakaturaDagger , Martin RoosDagger , Werner Müller-Esterl§, and Jasminka Godovac-ZimmermannDagger

From the Dagger  Institute of Molecular Biotechnology e.V., 07745 Jena, Germany, and the § Institute of Physiological Chemistry and Pathobiochemistry, Johannes Gutenberg University at Mainz, 55099 Mainz, Germany

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Rat bradykinin B2 receptor from unstimulated Chinese hamster ovary cells transfected with the corresponding cDNA has been isolated, and subsequent mass spectrometric analysis of multiple phosphorylated species and of the palmitoylation attachment site is described. Bradykinin B2 receptor was isolated on oligo(dT)-cellulose using N-(epsilon -maleimidocaproyloxy)succinimide-Met-Lys-bradykinin coupled to a protected (dA)30-mer. This allowed a one-step isolation of the receptor on an oligo(dT)-cellulose column via variation solely of salt concentration. After enzymatic in-gel digestion, matrix-assisted laser desorption ionization and electrospray ion trap mass spectrometric analysis of the isolated rat bradykinin B2 receptor showed phosphorylation at Ser365, Ser371, Ser378, Ser380, and Thr374. Further phosphorylation at Tyr352 and Tyr161 was observed. Rat bradykinin receptor B2 receptor is also palmitoylated at Cys356. All of the phosphorylation sites except for Tyr161 cluster at the carboxyl-terminal domain of the receptor located on the cytoplasmic face of the cell membrane. Surprisingly, many of the post-translational modifications were shown by MSn mass spectroscopic analysis to be correlated pairwise, e.g. diphosphorylation at Ser365 and Ser371, at Ser378 and Ser380, and at Thr374 and Ser380 as well as mutually exclusive phosphorylation at Tyr352 and palmitoylation at Cys356. The last correlation may be involved in a receptor internalization motif. Pairwise correlations and mutual exclusion of phosphorylation and palmitoylation suggest critical roles of multiple post-translational modifications for the regulation of activity, coupling to intracelluar signaling pathways, and/or sequestration of the bradykinin receptor.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Bradykinin, a member of the kinin family (1), is a nonapeptide with diverse biological activities ranging from a role in the inflammatory process to regulatory effects on vascular permeability, blood pressure, renal homeostasis, and pain generation (2, 3). Bradykinin mediates its physiological effects by binding to and activation of the bradykinin B2 receptor. Molecular cloning has revealed the primary structure of the B2 receptor (4) and classified it as a member of the G protein-coupled receptor superfamily. The consensus bradykinin receptor topology predicts four extracellular domains (ED11-4) and intracellular domains (ID1-4), each separated by seven transmembrane helical regions (TM1-7) spanning the lipid bilayer. B2 receptors are post-translationally modified by glycosylation (5), phosphorylation (6), and presumably by palmitoylation of the cytoplasmic surface.

Based on homology with other G protein-coupled receptors there have been indications regarding possible structural features probed by agonists, antagonists, and anti-idiotypic antibodies (5, 6), functional regions (7), and sites of post-transitional modifications for the B2 receptor (8). Site-directed mutagenesis indicated the importance of Tyr residues and of ID4 for the signaling and the uptake of the B2 receptor in receptor in rat-1 cells transfected with wild and mutant receptor cDNAs (9). However, as yet there is still rather little direct evidence at the protein level for attributes such as the precise sites and the roles of glycosylation, palmitoylation, and phosphorylation of bradykinin B2 or other G protein-coupled receptors. Indeed phosphorylation sites for few G protein-coupled receptors have been mapped to date (10-12), and most of these sites reflect the in vitro phosphorylation of the isolated receptor.

We report here on the isolation of rat B2 receptor from transfected Chinese hamster ovary (CHO) cells using oligo(dA) covalently linked to bradykinin via a specially developed bifunctional cross-linker. Affinity chromatography has been carried out under very mild conditions using oligo(dT) columns analogous to methods used for isolation of eukaryotic mRNA. In-gel digestion of electrophoretically separated receptor, subsequent peptide mass fingerprinting by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) or electrospray ionization (ESI) and fragment analysis by tandem (MS/MS) mass spectrometry have been used to characterize post-translational modifications of this receptor and its multiply phosphorylated species. The patterns of post-translational modifications which have been observed for the receptor under in vivo conditions show correlations among the various modifications and provide new information on their possible role(s) in the functional regulation of the bradykinin B2 receptor.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Ham's F-12 nutrient medium was from Life Technologies, Inc. Dithiothreitol Microselect, used for deprotecting the modified oligonucleotide, tetrabutylammoniumhydrogensulfate, and chymostatin were from Fluka. 1,10-Phenanthroline was from Merck. Hepes, N-(epsilon -maleimidocaproyloxy)succinimide (EMCS), phenylmethanesulfonyl fluoride, CHAPS, Ellman's reagent, bacitracine, bovine serum albumin, and MES were from Sigma. The Aquapore RP-300A HPLC column and chemicals for peptide sequencing were from Applied Biosystems. DNase-free RNase A was from Boehringer Mannheim. (dA)30 homomer with and without 5'-modification by 1-O-dimethoxytritylhexyldisulfide was from BioTeZ (Berlin). Met-Lys-bradykinin was from Bachem; trypsin was from Promega. Other chemicals (from Merck and Roth) were of the best grade available.

Synthesis of Polyadenylated Met-Lys-Bradykinin-- Met-Lys-bradykinin derivatized with EMCS at the epsilon -NH2 group of Lys2 was prepared by a synthesis similar to that used recently to prepare an analogous endothelin derivative (12). 1 mg (400 nmol) of Met-Lys-bradykinin was dissolved in 400 µl of 35% acetonitrile, 0.05% trifluoroacetate, further diluted with 50 mM sodium borate and 0.015% Triton X-305, pH 8.2, and a 10-fold excess (4 µmol) of the heterobifunctional cross-linker EMCS dissolved in 200 µl of acetonitrile was added. Subsequent steps in the reaction were carried out as described previously (12). The derivatized Met-Lys-bradykinin, N-(epsilon -maleimidocaproyloxy)succinimide-Met-Lys-bradykinin (EMC-MKBK), was purified on an Aquapore RP-300 column using a gradient of 0-70% acetonitrile in 0.1% trifluoroacetic acid. The purity of the fraction containing EMC-MKBK was checked by protein sequencing to confirm derivatization at Lys2 and by MALDI-TOF mass spectrometry (found MH+ 1513.9, expected 1513.6). (dA)30-5'-SS-R was used for attachment of 30-mer (dA) to the EMC-MKBK according to the procedure in Ref. 12. The (dA)30-5'-S-EMC-MKBK was purified on a Sephasil C18 column by applying a linear gradient of 2-70% acetonitrile in 0.1 M triethylammoniumacetate and 2 mM tetrabutylammoniumhydrogensulfate.

Cell Culture and Membrane Preparation-- CHO cells transfected with rat B2 receptor cDNA (4, 13) were grown in Ham's F-12 medium containing 10% fetal calf serum and 50 µg/ml streptomycin in a water-saturated, 5% CO2 atmosphere at 37 °C (13, 14). Cells grown to 80% confluence were harvested for membrane preparation by scraping in 100 mM NaCl, 10 mM Pipes at pH 6.8. The cells obtained were washed twice with the same buffer and subsequently resuspended in 2 mM EDTA, 10 mM Pipes at pH 6.8. All subsequent steps were carried out at 4 °C. Cell rupture was performed by Ultra-Turrax (IKA-Labortechnik, Staufen, Germany) at 20,000 rpm for 2 min. Membranes were collected by centrifugation at 30,000 × g for 10 min and resuspended in 100 mM NaCl, 2 mM EDTA, 10 mM Pipes at pH 6.8 to a final protein concentration of 2 mg/ml. The membrane suspension was stored at -80 °C.

Affinity Purification of Bradykinin B2 Receptor-- CHO membranes (600 µl) were suspended in 2 volumes of 20 mM potassium phosphate, pH 7.4, containing 4 mM CHAPS, 500 mM NaCl, 20 mM EDTA (buffer A). The mixture was stirred gently at 4 °C for 1 h and was then centrifuged at 100,000 × g for 1 h at 4 °C. The supernatants were incubated with 0.2 nmol of (dA)30-5'-S-EMC-MKBK for 1 h at 4 °C, 30 mg of oligo(dT)-cellulose was added, and the suspension was agitated gently at 4 °C for 2 h. The oligo(dT)-cellulose was pelleted by centrifugation (4 °C, 1,000 × g, 5 min) and packed into a microcolumn. The column was washed with 10 ml of buffer A at 4 °C and afterward eluted with 10 mM Tris/HCl, pH 7.4, 4 mM CHAPS, 1 mM EDTA. Fractions (50 µl each) containing B2 receptor were identified by SDS-polyacrylamide gel electrophoresis and immunoblot analysis.

Gel Electrophoresis and In-gel Tryptic Protein Digestion-- 10 µl of each fraction from the oligo(dT)-cellulose column was mixed with an equal volume of sample buffer containing 6% SDS, 10% (v/v) 2-mercaptoethanol, 20% (v/v) glycerol, 0.01% bromphenol blue, and 0.25 M Tris/HCl, pH 6.8, and brought to 95  °C for 2 min. Electrophoresis was performed in 10 or 12.5% polyacrylamide gels in the presence of 0.1% SDS at a constant current of 40 mA for 1.5 h (15). The resolved proteins were visualized by Coomassie Blue staining. After visualization, the gel was destained with a solution of 25 mM ammonium bicarbonate and 50% acetonitrile. The band corresponding to the B2 receptor was cut out and digested in the gel according to (16) as modified previously (12).

Mass Spectrometric Analysis-- For MALDI mass spectrometry, samples were dissolved in 5 µl of 50% acetonitrile, 0.1% trifluoroacetic acid and sonicated for few minutes. Aliquots of 0.5 µl were applied to a target disk and allowed to air dry. Subsequently, 0.3 µl of matrix solution (1% w/v alpha -cyano-4-hydroxycinnamic acid in 50% acetonitrile, 0.1% v/v trifluoroacetic acid) was applied to the dried sample and again allowed to dry. Spectra were obtained using a Bruker Biflex MALDI-TOF mass spectrometer. MS/MS analysis was carried out using a Finnigan MAT (San Jose, CA) LCQ ion trap mass spectrometer coupled on-line with a HPLC system (Hewlett Packard 1090). For the interpretation of MS and MS/MS spectra of protein digests we used the Sherpa software (17), the MS-Fit, MS-Tag, and MS-Product programs available at the UCSF web site (http://rafael.ucsf.edu/cgi-bin/msfit), the PepSearch programs at the EMBL web site (http://www.mann.embl-heidelberg.de/Services/PeptideSearch/FR_peptideSearchForm.html), and the PepFrag program at the Rockefeller University web site (http://prowl.rockefeller.edu/).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Isolation of Rat Bradykinin B2 Receptor from CHO Cells-- Rat bradykinin B2 receptor was isolated from CHO cells using a "fishhook" strategy similar to that recently applied successfully for isolation of another peptide receptor, endothelin B receptor (12). The fishhook consists of the receptor ligand (here MLBK) and a (dA)30 polynucleotide joined via the heterobifunctional cross-linking reagent EMCS which, in addition to a N-hydroxysuccinimide-activated ester, also possesses a thiol-selective maleimido group. This linker was attached to MKBK via the epsilon -amino group of Lys2, and the thiol-selective maleimido group was used to attach (dA)30. The final product, (dA)30-5'-S-EMC-MKBK, was subsequently added to a suspension of CHO cell membranes solubilized in the non-ionic detergent CHAPS. B2 receptors bound to (dA)30-5'-S-EMC-MKBK were purified in a manner similar to that used for the isolation of eukaryotic mRNA: absorption on oligo(dT)-cellulose, washing in the presence of high salt concentrations, which favor the formation of a poly(dA·dT) double helix, and elution with very low salt concentrations that destabilize a poly(dA·dT) double helix. Recombinant B2 receptor is highly expressed in the transfected CHO cells used for the present experiments (1.3 pmol/mg of protein (13)) and shows a strong band at about 42 kDa in SDS-polyacrylamide gel electrophoresis of total membrane proteins (lane 1, Fig. 1). This band is strongly enriched relative to other membrane proteins by the fishhook purification strategy (lane 2, Fig. 1). Subsequent analysis of this band (Fig. 1, lane 2) revealed that it contains highly pure B2 receptor suitable for detailed analysis by mass spectrometry. By comparison with intensities from the unpurified extract of membrane proteins, we estimate that about 70% of cellular B2 receptor was recovered after fishhook purification.


View larger version (96K):
[in this window]
[in a new window]
 
Fig. 1.   Purification of rat bradykinin B2 receptor from CHO cells with (dA)30-5'-S-EMC-MKBK/oligo(dT)-cellulose. The elution profile of the receptor protein from an oligo(dT)-cellulose column monitored by 10% SDS-polyacrylamide gel electrophoresis with Coomassie Blue staining is shown. Lane 1, total membrane proteins prior to isolation of B2 receptor; lanes 2-4, the first three fractions eluted from the oligo(dT) column; lane 5, molecular mass marker proteins. The molecular mass of the rat bradykinin B2 receptor is indicated at the left.

Identification of Tryptic Fragments of Rat B2 Receptor-- Bands corresponding to Coomassie Blue-stained bradykinin B2 receptor were cut out from the SDS-polyacrylamide gels and subjected to in-gel tryptic digestion. MALDI mass spectrometry was used for the initial analysis of the entire mixture of tryptic peptides. From the MALDI spectra it was possible to identify peptides from the extracellular domains ED3 as well as peptides from cytoplasmic regions ID2, ID3, and ID4. Peptides containing TM helical regions TM3-TM5 joined to the corresponding loop region(s) could also be observed (Fig. 2 and Table I). In the present studies we did not observe peptides from domains ED1, TM1, ID1, TM2, and ED2 (Fig. 2) presumably because this region of the B2 receptor has only two internal sites for tryptic hydrolysis at positions 10 and 91 and therefore would be expected to yield large, hydrophobic peptides except for the extreme amino-terminal peptide of 10 residues.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 2.   Peptides identified by MALDI-TOF mass spectrometry of rat B2 receptor. Solid lines denote tryptic peptides identified from the tryptic peptide mixture. Filled black circles with white letters indicate post-translationally modified amino acid residues. Amino acid residues have been numbered according to the full-length B2 receptor identified recently (4, 43).

                              
View this table:
[in this window]
[in a new window]
 
Table I
MALDI mass spectrometry analysis of B2 receptor tryptic peptides

Identification of Post-translationally Modified Peptides-- The MALDI mass measurements gave clear indications of which peptides were post-translationally modified (Table I). We observed phosphorylation for peptides 6-7, 26-31, 28-31, and 32-33. Peptides 6-7, 26-31, and 28-31 showed an increased mass of 80 Da, which is characteristic for peptides with single phosphorylation sites. For peptide 32-33, a mass consistent with a diphosphorylated peptide was observed. For peptide 30-31, palmitoylation was suggested by an increase in mass of 238 Da. The identity of the peptides was confirmed by electrospray ion trap mass spectrometry of the unseparated peptide mixture with subsequent MS/MS analysis of selected fragments of interest. It is known that in electrospray ion trap mass spectrometry the phosphorylated peptides partially lose the H3PO4 moiety in the mass spectrometer, thus producing a pair of peaks separated by a mass difference of 98 Da (18). In accordance with this, we observed that phosphopeptides 6-7, 26-31, and 28-31 could be identified by a pair of masses 80 Da higher (the mass of H3PO4 minus H2O) and 18 Da lower than expected based on the amino acid sequence. For the peptide 32-33 the loss of two H3PO4 moieties confirmed the presence of two phosphorylation sites. We conclude that intracellular domains ID2 and ID4 of the rat B2 receptor are modified by phosphorylation (ID2, ID4) and palmitoylation (ID4).

Identification of Phosphorylation Sites-- For the peptide 26-31, a m/z of 1992.2 Da was observed in the MALDI-TOF spectra. There were two pairs of peaks separated by 98 Da (m/z 1992.2 and 1895.8 Da). In addition the MS/MS ESI spectrum of peptide 26-31 (Fig. 3A) showed a y ion series, y15, y14, y13, y12, y9, y8, y7, and a b ion series, b15, b14, b13, b12, b11, b9, b8, and b7, which was sufficient to identify Tyr352 and not Ser348 in the amino acid sequence 344FRKKSREVY(Pi)QAICRK358 as the site of phosphorylation. The presence of the w11 ion confirmed that Ser348 is not phosphorylated. For peptide 6-7 an increase of 80 Da was observed, suggesting that the peptide 161YLALVKTMSMGR171 is phosphorylated at Tyr161 or Ser168. MS/MS analysis generated y12 and y11 ions as well as b12, b11, b10, and b7 ions that were sufficient to determine that Tyr161 is the phosphorylation attachment site.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 3.   Electrospray mass spectroscopic analysis of tryptic peptides. Panel A, MS/MS spectra of phosphopeptides 26-31, 344FRKKSREVY(Pi)QAICRK358 (M+H)+. Panel B, MS/MS spectra of diphosphopeptide 32-33, 359GGCMGESVQMENSMGTLRTSISVDR383 (M+2H)2+. Inset, MS3 analysis of peptide y12-pp. The fragment y2+25-pp with the loss of one or two phosphate groups is indicated by the ions y25 (-49) and y25 (-98), respectively. Panel C, palmitoylated peptide 30-31, 350EVYQAIC(pal)RK358 (M+2H)2+. The symbols p and pp denote fragment ions with one or two attached phosphate groups, respectively.

For the peptide 32-33, 359GGCMGESVQMENSMGTLRTSISVDR383, the MALDI-TOF mass spectra gave a parent ion with an m/z of 2806.4 corresponding to this peptide with two phosphate groups attached. No ions corresponding to this peptide with more or fewer than two phosphate groups could be detected. Given that this peptide has six potential phosphorylation sites, Ser at positions 365, 371, 378, and 380 and Thr at 374 and 377, this was a first indication that phosphorylation of this peptide does not involve uncoordinated phosphorylation of these sites. Further evidence for correlation among the sites that are phosphorylated in this peptide has been obtained from ion trap ESI mass spectra after fragmentation of this peptide (Fig. 3B). Initial inspection of the MS/MS spectra clearly indicated a very complicated phosphorylation pattern for this peptide. From the y2+ and b2+ series of fragments, clear evidence of concurrent phosphorylation at Ser365 and Ser371 was obtained from the fragments y2+12 and b2+14-pp (Fig. 4A, note that one or two attached phosphate groups are indicated by -p or -pp in the following text and in Fig. 4). Other fragments that would be consistent with this phosphorylation pattern include y2+18-p, y2+16-p, and y2+5 as well as b2+19-pp, b2+17-pp, and b2+12-p. Similarly, the fragment y2+6-pp-98, which corresponds to the peptide y2+6-pp with the loss of two phosphate groups, gives clear evidence for concurrent phosphorylation at Ser378 and Ser380. Other fragments that would be consistent with concurrent phosphorylation of these two serines include y2+18-pp, y2+14-pp, y2+12-pp, and y2+4-p as well as b2+21-p. (Fig. 4). There are three fragments, y2+7-p, y2+6-p, and b2+18-p which cannot be consistent with the the above two types of diphosphorylation and which require phosphorylation at one of Ser365, Ser371, or Thr374 as well as at one of Thr377, Ser378, or Ser380. Evidence for concurrent phosphorylation at Thr374 and Ser380 was obtained by MS3 analysis of the y series fragment y2+12-pp (Figs. 3B, inset, and 4B).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 4.   Schematic of the analysis of phosphorylation patterns for the diphosphorylated peptide 359GGCMGESVQMENSMGTLRTSISVDR383. Panel A, ESI ion trap MS/MS fragmentation of the parent ion m/z 2806.4. The standard numbering of the b2+ series ions (above) and y2+ series ions (below) is indicated on the sequence of this peptide. The six potential phosphorylation sites are indicated by the encircled serine and threonine residues and the amino acid residue numbers at the top of the figure. Starting either from the parent ion b2+25-pp or the parent ion y2+25-pp, b2+ series and y2+ series fragment ions that were observed are shown above or below the peptide sequence, respectively. The number of attached phosphate groups is indicated by the label of the ion, e.g. y2+18-p indicates the peptide fragment VQMENSMGTLRTSISVDR with one attached phosphate group. Fragment ions that can arise from diphosphorylation at Ser365 and Ser371, at Ser378 and Ser380, and at Thr374 and Ser380 are indicated by solid, dash, and dot-dash lines, respectively. Fragment ions that may arise from more than one of the diphosphorylation patterns are indicated by dotted lines. Open, gray, and solid circles denote phosphorylation sites that, respectively: are not phosphorylated (open circle ), belong to a group of potential phosphorylation sites where the actual site of phosphorylation cannot be ascertained from the fragment ion (), or are phosphorylated (). For example, the ions y2+25-pp and y2+18-p indicate phosphorylation at Ser365 with a second phosphorylation site at any one of Ser371, Ser378, Ser380, Thr374, or Thr377. Panel B, ESI ion trap MS3 analysis of peptide y2+12-pp. Panel C, the three diphosphorylation patterns that are necessary and sufficient to explain all MS results.

The three concurrent phosphorylation patterns shown in Fig. 4C suffice to explain all observed fragments. Evidence that other patterns of diphosphorylation probably do not exist was obtained by MS3 analysis of fragments y2+16-p, which indicated that when Ser365 is phosphorylated, the only concurrent phosphorylation site is Ser371, and of y7-pm which indicated that Thr377 is probably never phosphorylated, at least under the conditions to which the CHO cells were subjected in the present experiments. Given that diphosphorylation of the five sites Ser365, Ser371, Ser378, Ser380, and Thr374 could occur in 10 different combinations, the present evidence that only three of these combinations occur is strong evidence for coordinated diphosphorylation. We confirmed these results with many more NH2-terminal (b2+H2O, b2+NH3, b2+H3PO4), COOH-terminal (y2+H2O, y2+NH3, y2+H3PO4), and internal fragment ions, which for clarity have been omitted from further discussion here, but were of considerable help during the course of spectra analysis.

Palmitoylation of B2 Receptor-- The increase of 238 Da in the mass of peptide 30-31 indicated the presence of a palmitate residue (Table I). The MS/MS analysis generated y92+, y82+, y72+, y62+, y52+, y42+, y32+, and b42+, b52+, b62+, b72+, b82+, b92+ ions showing that Cys356 in peptide 350EVYQAICRK358 is palmitoylated (Fig. 3C). MS/MS analysis of this peptide showed no phosphorylation at Tyr352 (Fig. 3C). Conversely, MS/MS analysis of peptide 344FRKKSREVY(Pi)QAICRK358 demonstrated phosphorylation at residue Tyr352 but not palmitoylation at Cys356 (Fig. 3A). This result was confirmed by MS/MS analysis of peptide 347KSREVY(Pi)QAICRK358 (not shown). In the MALDI mass spectra we were able to find masses corresponding to peptides 25-31, 26-33, and 28-32 (Table I) with no phosphorylation at Tyr352 or palmitoylation at Cys356, but no masses were detected which correspond to peptides with simultaneous phosphorylation and palmitoylation of Tyr352 and Cys356, respectively. Together these results indicate a mutually exclusive palmitoylation at Cys356 or phosphorylation at Tyr352 of intracelluar domain ID4 of the rat B2 receptor.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Post-translational modifications such as phosphorylation are a widespread mechanism thought to regulate the desensitization, internalization, and resensitization of G protein-coupled receptors. For two prototypic receptors, i.e. rhodopsin and beta 2-adrenergic receptor, the phosphorylation sites have been studied in some detail (9-11, 19-21). Typically serine and threonine residues located in the carboxyl-terminal domains of these receptors are phosphorylated in response to light (rhodopsin) or ligand (adrenergic receptors). Because of their extremely low abundance in the cell, ligand-dependent G protein-coupled receptors have been notoriously refractory to chemical analysis of phosphorylation sites in vivo, and major discrepancies between the mapping of phosphorylation sites in vitro and the effect of corresponding mutations in vivo have been reported (22). In the present work we took advantage of a highly sensitive technique, i.e. mass fingerprinting (23, 24), to map post-translationally modified peptides from a typical G protein-coupled peptide hormone receptor isolated from transfected CHO cells by a novel fishhook technique. Tryptic peptides could be recovered from a large part of the sequence of the B2 receptor including, except for Thr92 and Thr95 of ID1, all those sequence regions that might be expected to show post-translational modifications by phosphorylation or fatty acid attachment. MALDI, ESI mass spectrometry and MSn analysis revealed that the B2 receptor is phosphorylated at Ser365, Ser371, Ser378, Ser380, and Thr374. Further, we observed phosphorylation at Tyr161 and at Tyr352 and palmitoylation at Cys356.

A number of previous studies on bradykinin B2 receptor cloned into CHO cells (13, 25-28) have indicated that binding affinities for bradykinin and physiological responses to cell stimulation with bradykinin are similar to those observed in primary cell types. Because the receptor was isolated from unstimulated cells, the observed phosphorylation sites most probably represent the "basal" pattern of phosphorylation caused by intrinsic receptor activity (22), although there might be some contribution from accidentally released ligands, e.g. from culture medium supplemented with fetal calf serum, which is a rich source of kininogens (29). However, basal phosphorylation in the absence of a ligand, which was not inhibited by antagonists, has previously been shown for human bradykinin B2 receptor in human foreskin fibroblast cells (30), suggesting that such basal phosphorylation may not be unusual.

Phosphorylation and palmitoylation are major mechanisms that modulate signal transduction and internalization of many G protein-coupled receptors (31-35). Except for Ser365, all post-translational modification sites observed in the present work are strongly conserved in all known B2 receptors, and the present work provides some new information on the possible roles of post-translational modification of these sites. For example, residue Tyr161 is highly conserved in all known sequences of B2 receptor with Tyr161 being a part of the DRY motif that is conserved in the family of G protein-coupled receptors. Because Tyr161 seems to play a significant role in G protein coupling of the B2 receptor (9), our present results suggest that phosphorylation of this critical residue may modulate the signaling capacity of this receptor. Similar phosphorylation of the DRY motif might be important for other G protein-coupled receptors.

Out of 7 Ser/Thr residues present in the carboxyl-terminal domain ID4 of the B2 receptor, five phosphorylation sites at Ser365, Ser371, Ser378, Ser380, and Thr374 have been identified. Previous work has demonstrated that truncation of 34 residues at the carboxyl-terminal tail of the rat B2 receptor has a major impact on receptor internalization (36) thus further supporting the notion that phosphorylation and sequestration of the receptor may be causally linked (9). An unexpected finding of this study is that phosphorylation of region ID4 of the B2 receptor involves three different molecular species with diphosphorylation at Ser365 and Ser371, at Ser378 and Ser380, and at Thr374 and Ser380. The observations that only diphosphorylation apparently occurs and that the sites are correlated has important implications for attempts to analyze functional aspects of the bradykinin B2 receptor, e.g. it seems essential to know the patterns of correlated phosphorylation prior to mutation of phosphorylation sites and the measurement of resultant physiological responses. Indeed, the present results suggest that in mutation experiments it is potentially possible not only to block phosphorylation at some sites, but perhaps also to create novel phosphorylation patterns that do not exist in the natural receptor, with potentially aberrant physiological responses (21).

Present results also allow a new suggestion for the role in internalization of the Tyr352 and Cys356, both of which are strongly conserved in bradykinin B2 receptors. Site-directed mutagenesis of rat-1 cells suggested that these residues may define an important site in B2 receptor internalization but may contribute to the specificity of the site by phenol ring itself or the amino acid bulk rather than by phosphorylation (9). Our results showed that rat B2 receptor is phosphorylated at Tyr352 in CHO cells. The phosphorylated residue Tyr352 is sequentially close to Cys356, which our results showed to be palmitoylated.

Another unanticipated finding of this study is the apparently mutually exclusive phosphorylation at Tyr352 and palmitoylation at Cys356. Because these residues are sequentially juxtaposed one may speculate that in the nonacylated form of the B2 receptor residue Tyr352 is available to tyrosine kinase(s), whereas anchoring of the corresponding region in the membrane in the palmitoylated form prevents their access. This scenario is reminiscent of observations made for the beta 2-adrenergic receptor (37) where a complete desensitization of the nonpalmitoylated receptor was observed because of hyperphosphorylation of two residues (Ser345/Ser346) located next to the critical Cys341 residue used for fatty acid derivatization (38). Because of the many divergent roles that have been postulated for receptor palmitoylation (39-42), the direct demonstration in this work of fatty acid derivatization of the bradykinin B2 receptor at Cys356 suggests that further investigation of the role of palmitoylation in the kinin receptor is needed.

It is clear from the present results that it is not sensible to speak of "the basal state" of bradykinin receptor in terms of a single molecular species. It is highly likely that the same applies to "the stimulated state" and that, as is beginning to be evident with other receptors (9-11, 19-21), a very complex set of temporal and spatial changes involving a substantial number of correlated post-translational modifications of the receptor will have to be elucidated in order to relate such modifications to physiological pathways. The present results demonstrate that such modifications can be detected and directly characterized for receptors modified under in vivo conditions and provide indications of the kinds of directed mutagenesis experiments that are likely to be helpful in resolving the probably very complex relationships between post-translational modifications and physiological pathways for bradykinin and probably other G protein-coupled receptors.

At the present state of knowledge about G protein-coupled receptors, the large number of post-translational modifications observed for the B2 receptor, and particularly the correlation of modifications at different sites, was unanticipated and suggests that the number and diversity of post-translational modifications of such receptors, together with concomitant roles in signal transduction pathways, may be much more complex than presently realized. Taken together with recent analogous results on endothelin B receptor (12), it appears that the types of isolation procedures and mass spectrometry analyses established in the present work for direct analysis of modifications in in vivo systems at the protein level will be suitable, perhaps essential, for relating specific post-translational modifications to functional states of the bradykinin receptor. In this context, it may be noted that we have recently established "functional proteomics" methods for observing complex, time-dependent phosphorylation/dephosphorylation responses for large numbers of downstream proteins following receptor stimulation (44, 45). Together with the present methods, this potentially allows correlation under in vivo conditions of specific post-translational modifications of bradykinin receptor with downstream responses.

    ACKNOWLEDGEMENT

We thank Dr. Kurt Jarnagin, Palo Alto, for the generous gift of rat B2 receptor cDNA.

    FOOTNOTES

* This work was supported by Deutsche Forschungsgemeinschaft Grants Go-639/1-2 and Mu-598/4-3.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Present address: University College London, Centre for Molecular Medicine, 5 University St., London WC1E 6JJ, United Kingdom. To whom correspondence should be addressed. Tel.: 44-171-209-6185; Fax: 44-171-209-6211; E-mail: j.godovac-zimmermann{at}ucl.ac.uk.

    ABBREVIATIONS

The abbreviations used are: ED, extracellular domain(s); ID, intracellular domain(s); TM, transmembrane domain(s); CHO, Chinese hamster ovary; MALDI, matrix-assisted laser desorption ionization; TOF, time of flight; ESI, electrospray ionization; MS/MS, tandem mass spectrometry; EMCS, N-(epsilon -maleimidocaproyloxy)succinimide; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; MES, 4-morpholineethanesulfonic acid; HPLC, high performance liquid chromatography; 5'-SS-R, 1-O-dimethoxytritylhexyldisulfide; (dA)30-5'-S-EMC-BK, (dA)30-5'-S-N-(epsilon -maleimidocaproyloxy)succinimide; MKBK, Met-Lys-bradykinin; EMC-MKBK, N-(epsilon -maleimidocaproyloxy)succinimide Met-Lys-bradykinin; Pipes, 1,4-piperazinediethanesulfonic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Rocha e Silva, M., Beraldo, W. T., and Rosenfeld, G. (1949) Am. J. Physiol. 156, 261-273
  2. Regoli, D., and Barabe, J. (1980) Pharmacol. Rev. 32, 1-46[Medline] [Order article via Infotrieve]
  3. Margolius, H. S. (1989) Annu. Rev. Pharmacol. Toxicol. 29, 343-364[CrossRef][Medline] [Order article via Infotrieve]
  4. McEachern, A. E., Shelton, E. R., Bhakta, S., Obernolte, R., Bach, C., Zuppan, P., Fujisaki, J., Aldrich, R. W., and Jarnagin, K. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 7724-7728[Abstract]
  5. Abd Alla, S., Buschko, J., Quitterer, U., Maidhof, A., Haasemann, M., Breipohl, G., Knolle, J., and Müller-Esterl, W. (1993) J. Biol. Chem. 268, 17277-17285[Abstract/Free Full Text]
  6. Ottleben, H., Haasemann, M., Ramachandran, R., Görlach, M., Müller-Esterl, W., and Brown, L. R. (1997) Eur. J. Biochem. 244, 471-478[Abstract]
  7. Abd Alla, S., Quitterer, U., Grigoriev, S., Maidhof, A., Haasemann, M., Jarnagin, K., and Müller-Esterl, W. (1996) J. Biol. Chem. 271, 1748-1755[Abstract/Free Full Text]
  8. Blaukat, A., Abd Alla, S., Lohse, M., and Müller-Esterl, W. (1996) J. Biol. Chem. 271, 32366-32374[Abstract/Free Full Text]
  9. Prado, G. N., Taylor, L., and Polger, P. (1997) J. Biol. Chem. 272, 14638-14642[Abstract/Free Full Text]
  10. Papac, D. I., Oatis, J. E., Crouch, R. K., and Knapp, D. R. (1993) Biochemistry 32, 5930-5934[Medline] [Order article via Infotrieve]
  11. Papac, D., Thornburg, K. R., Büllesbach, E. E., Crouch, R., and Knapp, D. R. (1992) J. Biol. Chem. 267, 16889-16894[Abstract/Free Full Text]
  12. Roos, M., Soskic, V., Poznanovic, S., and Godovac-Zimmermann, J. (1998) J. Biol. Chem. 273, 924-931[Abstract/Free Full Text]
  13. Quitterer, U., Schröder, C., Müller-Esterl, W., and Rehm, H. (1995) J. Biol. Chem. 270, 1992-1999[Abstract/Free Full Text]
  14. Tippmer, S., Quitterer, U., Kolm, V., Faussner, A., Rocher, A., Mosthaf, L., Müller-Esterl, W., and Häring, H. (1994) Eur. J. Biochem. 225, 297-304[Abstract]
  15. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
  16. Hellman, U., Wernstedt, C., Gonez, J., and Heldin, C.-H. (1995) Anal. Biochem. 224, 451-455[CrossRef][Medline] [Order article via Infotrieve]
  17. Taylor, J. A., Walsh, K., and Johnson, R. S. (1996) Rapid Commun. Mass Spectrom. 10, 679-687[CrossRef][Medline] [Order article via Infotrieve]
  18. Szczepanowska, J., Zhang, X., Herring, C. J., Qin, J., Korn, E. D., and Brzeska, H. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 8503-8508[Abstract/Free Full Text]
  19. Ohguro, H., Van Hooser, J. P., Milam, A. H., and Palczweski, K. (1995) J. Biol. Chem. 270, 14259-14262[Abstract/Free Full Text]
  20. Ohguro, H., Rudnicka-Nawrot, M., Buczylko, J., Zhao, X., Taylor, J. A., Walsh, K. A., and Palczweski, K. (1996) J. Biol. Chem. 271, 5215-5224[Abstract/Free Full Text]
  21. Fredericks, Z. L., Pitcher, J. A., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 13796-13803[Abstract/Free Full Text]
  22. Seibold, A., January, B. G., Friedman, J., Hipkin, R. W., and Clark, R. B. (1998) J. Biol. Chem. 273, 7637-7642[Abstract/Free Full Text]
  23. Shevchenko, A., Jensen, O. N., Podtelejnikov, A. V., Sagliocco, F., Wilm, M., Vorm, O., Mortensen, P., Shevscenko, A., Boucherie, H., and Mann, M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 14440-14445[Abstract/Free Full Text]
  24. Wilkins, M. R., Pasquali, C., Appel, R. D., Ou, K., Golaz, O., Sanchez, J. C., Yan, J. X., Gooley, A. A., Hughes, G., Humphery-Smith, I., Williams, K. L., and Hochstrasser, D. F. (1996) Bio/Technology 14, 61-65[Medline] [Order article via Infotrieve]
  25. Park, J., Freedman, R., Bach, C., Yee, C., Rohrwild, M., Kaminishi, H., Müller-Esterl, W., and Jarnagin, K. (1994) Braz. J. Med. Biol. Res. 27, 1704-1724
  26. Minshall, R. D., Tan, F., Hakamura, F., Rabito, S. F., Becker, R. P., Marcic, B., and Erdös, E. G. (1997) Circ. Res. 81, 848-856[Abstract/Free Full Text]
  27. Taketo, M., Yokoyama, S., Kimura, Y., and Higashida, H. (1997) Biochim. Biophys. Acta 1355, 89-98[Medline] [Order article via Infotrieve]
  28. Eggerickx, D., Raspe, E., Bertrand, D., Vassart, G., and Parmentier, M. (1992) Biochem. Biophys. Res. Commun. 187, 1306-1313[Medline] [Order article via Infotrieve]
  29. Samama, P., Cotecchia, S., Costa, T., and Lefkowitz, R. (1993) J. Biol. Chem. 268, 4625-4636[Abstract/Free Full Text]
  30. Blaukat, A., Abd Alla, S., Lohse, M. J., and Müller-Esterl, W. (1996) J. Biol. Chem. 271, 32366-32374[Abstract/Free Full Text]
  31. Hill-Eubanks, D., Burstein, E. S., Spalding, T. A., Brauner-Osborn, H., and Brann, M. R. (1996) J. Biol. Chem. 271, 3058-3065[Abstract/Free Full Text]
  32. Hawes, B. E., Luttrell, L. M., Exum, S. T., and Lefkowitz, R. J. (1994) J. Biol. Chem. 269, 15776-15785[Abstract/Free Full Text]
  33. Thompson, P., and Findlay, J. B. C. (1984) Biochem. J. 220, 773-780[Medline] [Order article via Infotrieve]
  34. Ovchinikov, Y. A., Abdulaev, N. G., and Bogachuk, A. S. (1988) FEBS Lett. 230, 1-5[CrossRef][Medline] [Order article via Infotrieve]
  35. Krueger, K. M., Daaka, Y., Pitcher, A. A., and Lefkowitz, R. J. (1997) J. Biol. Chem. 272, 5-8[Abstract/Free Full Text]
  36. Trowbridge, I. S., Collown, J. F., and Hopkins, C. R. (1993) Annu. Rev. Cell Biol. 9, 129-161[CrossRef]
  37. Moffet, S., Adam, L., Bonin, H., Loisel, T. P., Bouvier, M., and Mouillac, B. (1996) J. Biol. Chem. 271, 21490-21497[Abstract/Free Full Text]
  38. Moffet, S., Mouillac, B., Bonin, H., and Bouvier, M. (1993) EMBO J. 12, 349-356[Abstract]
  39. Horstmeyer, A., Cramer, H., Sauer, T., Müller-Esterl, W., and Schroeder, C. (1996) J. Biol. Chem. 271, 20811-20819[Abstract/Free Full Text]
  40. Eason, M. G., Jacinto, M. T., Theiss, C. T., and Liggett, S. B. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11178-11182[Abstract/Free Full Text]
  41. Mouillac, B., Caron, M., Bonin, H., Dennis, M., and Bouvier, M. (1992) J. Biol. Chem. 267, 21733-21737[Abstract/Free Full Text]
  42. Khouja, A., and Jones, C. T. (1992) J. Dev. Physiol. 18, 263-270[Medline] [Order article via Infotrieve]
  43. Abd Alla, S., Godovac-Zimmermann, J., Braun, A., Roscher, A. A., Müller-Esterl, W., and Quitterer, U. (1996) Biochemistry 35, 7514-7519[CrossRef][Medline] [Order article via Infotrieve]
  44. Soskic, V., Görlach, M., Poznanovic, S., Boehmer, F.-D., and Godovac-Zimmermann, J. (1999) Biochemistry 38, 1757-1764[CrossRef][Medline] [Order article via Infotrieve]
  45. Godovac-Zimmermann, J., Soskic, V., Poznanovic, S., and Brianza, F. (1999) Electrophoresis, in press


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.